TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling.

Breast cancers expressing estrogen receptor-alpha (ERalpha) are associated with a favorable biology and are more likely to respond to hormonal therapy. In addition to ERalpha, other pathways of estrogen response have been identified including ERbeta and GPR30, a membrane receptor for estrogen, and the key mechanisms regulating expression of ERs and hormone response remain controversial. Herein, we show that TFAP2C is the key regulator of hormone responsiveness in breast carcinoma cells through the control of multiple pathways of estrogen signaling. TFAP2C regulates the expression of ERalpha directly by binding to the ERalpha promoter and indirectly via regulation of FoxM1. In so doing, TFAP2C controls the expression of ERalpha target genes, including pS2, MYB, and RERG. Furthermore, TFAP2C controlled the expression of GPR30. In distinct contrast, TFAP2A, a related factor expressed in breast cancer, was not involved in estrogen-mediated pathways but regulated expression of genes controlling cell cycle arrest and apoptosis including p21(CIP1) and IGFBP-3. Knockdown of TFAP2C abrogated the mitogenic response to estrogen exposure and decreased hormone-responsive tumor growth of breast cancer xenografts. We conclude that TFAP2C is a central control gene of hormone response and is a novel therapeutic target in the design of new drug treatments for breast cancer.

[1]  R. Weigel,et al.  Tumor Suppressor Activity of AP2α Mediated through a Direct Interaction with p53* , 2002, The Journal of Biological Chemistry.

[2]  Lisa A. McPherson,et al.  AP2alpha and AP2gamma: a comparison of binding site specificity and trans-activation of the estrogen receptor promoter and single site promoter constructs. , 1999, Nucleic acids research.

[3]  J. Polman,et al.  ER beta: identification and characterization of a novel human estrogen receptor. , 1996, FEBS letters.

[4]  B. Lokeshwar,et al.  Insulin-like growth factors and their binding proteins in prostate cancer: cause or consequence? , 2006, Urologic oncology.

[5]  W. El-Deiry,et al.  AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression , 1997, Nature Genetics.

[6]  R. Weigel,et al.  Genomic structure of the promoters of the human estrogen receptor-alpha gene demonstrate changes in chromatin structure induced by AP2gamma. , 2001, The Journal of biological chemistry.

[7]  J. Pietenpol,et al.  Kinetics of p53 Binding to Promoter Sites In Vivo , 2001, Molecular and Cellular Biology.

[8]  Eric R. Prossnitz,et al.  A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling , 2005, Science.

[9]  R. Weigel,et al.  Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. , 1997, Genomics.

[10]  K. Cowan,et al.  Posttranscriptional regulation of the c-myb proto-oncogene in estrogen receptor-positive breast cancer cells. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  X. Shu,et al.  IGFBP3 mRNA expression in benign and malignant breast tumors , 2007, Breast Cancer Research.

[12]  P Chambon,et al.  Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. , 1984, Nucleic acids research.

[13]  K. Bland,et al.  Estrogen Action Via the G Protein-Coupled Receptor , GPR 30 : Stimulation of Adenylyl Cyclase and cAMP-Mediated Attenuation of the Epidermal Growth Factor Receptor-to-MAPK Signaling Axis , 2001 .

[14]  K. Bickenbach,et al.  Aromatase inhibitors: an overview for surgeons. , 2006, Journal of the American College of Surgeons.

[15]  David Botstein,et al.  RERG Is a Novel ras-related, Estrogen-regulated and Growth-inhibitory Gene in Breast Cancer* , 2001, The Journal of Biological Chemistry.

[16]  R. Coombes,et al.  Breast Estrogen and Progesterone Receptors in the Normal Female Updated Version , 2006 .

[17]  R. Weigel,et al.  Identification of ERF-1 as a member of the AP2 transcription factor family. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Weigel,et al.  PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer. , 2000, Cancer research.

[19]  V. Jordan,et al.  Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast. , 1988, Critical reviews in clinical laboratory sciences.

[20]  E. Lam,et al.  The Forkhead Box M1 Protein Regulates the Transcription of the Estrogen Receptor α in Breast Cancer Cells* , 2006, Journal of Biological Chemistry.